Skip to main content
. 2015 Nov 13;7(1):638–655. doi: 10.18632/oncotarget.6313

Figure 6. Validation of the role of PP2A in the cytotoxic effects of EMQA and paclitaxel combination treatment.

Figure 6

(A) The PP2A activities of A549 cells were determined after exposure to EMQA 5 μM and/or paclitaxel 10 nM for 24 hours. Bar, mean; error bars, S.D. (n = 3) (B) The effects of EMQA and/or paclitaxel on all the sub-units of PP2A complex. Representative western blot images of three identical experiments were shown. (C) Co-treatment with PP2A inhibitor, okadaic acid (OA), reduced the effects of EMQA and paclitaxel combination treatment on p-Akt and apoptosis. A549 and H460 cells were treated with EMQA 5 μM plus paclitaxel 10 nM and/or OA 100 nM for 24 hours and analyzed by flow cytometry and western blot. Bar, mean; error bars, S.D. (n = 3) Downregulating PP2Ac by siRNA diminished the pro-apoptotic effects of EMQA and paclitaxel combination treatment in A549 cells. A549 cells were first transfected with PP2Ac siRNA or mock for 24 hours and exposed to EMQA 5 μM plus paclitaxel 10 nM for 24 hours. Cell apoptosis was analyzed by flow cytometry and the associated molecular alterations were analyzed by western blot. Bar, mean; error bars, S.D. (n = 3).